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BACKGROUND: Ectopic pregnancy (EP) is the leading cause of maternal death in the first trimester of pregnancy. 
There are many variables which can predispose EP. The aim of this study was to evaluate the possible association 
between individual’s response to given medical treatment and predicting factors of ectopic pregnancy among 
pregnant women. 
METHODS: In this cross-sectional study, 277 patients with ectopic pregnancy who were admitted to obstetrics and 
gynecology ward of Besat hospital, Sanandaj, Iran, were evaluated. The necessary information was obtained from 
all women diagnosed with EP during 2008 to 2013. Patients who received any medication before study or those 
who could not use methotrexate (MTX) were excluded from study. 
RESULTS: In this study, 205 (74.1%) patients responded to the medical therapy. There was a significant 
association between successful response to the treatment and beta human chorionic gonadotropin (β-hCG) serum 
level less than 5000 mIU/ml, pregnancy sac size less than 4 cm and lack of fetal heart rate (FHR) in transvaginal 
sonography (TVS). 
CONCLUSION: In conclusion, it was found that β-hCG serum level, pregnancy sac size and presence of FHR play a 
key role in predicting the response to the medical treatment in women with ectopic pregnancy, and might be 
helpful in selecting appropriate therapeutic scheme. 
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Introduction1 
Ectopic pregnancy (EP) is a major health 
problem for women in child-bearing age. It 
states the pregnancy occurring outside the 
uterine cavity that constitutes 1.2–1.4% of all 
reported pregnancies.1 In this phenomenon 
blastocyst implants outside the uterine cavity 
endometrium, mostly (95.5%) in the fallopian 
tube.2,3 The other most common implantation 




sites are ovarian (3.2%) and abdominal (1.3%) 
sites.4 
Treatment for EP includes surgical or 
medical treatment which is usually systemic or 
through local route, or by expectant 
treatment.5 According to the American College 
of Obstetricians and Gynecologists (ACOG) 
guideline, when beta human chorionic 
gonadotropin (β-hCG) level is < 200 mIU/ml, 
which is further in decline phase, expectant 
management may play a role.6 
The favourable prognostic signs of ectopic 
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are absent or there are minimal clinical 
symptoms with no evidence of haemodynamic 
and low initial β-hCG serum level.7 
Previously, it has been reported that the 
medical treatment is quite less expensive than 
surgery.8 Different medications have been 
tried to treat ectopic pregnancies, including 
systemic or local methotrexate (MTX), local 
potassium chloride, hyperosmolar glucose, 
prostaglandins, danazol, etoposide, and 
mifepristone.9,10 Today, therapies mainly focus 
on MTX treatment. This agent was first used 
for supporting the surgical removal of the 
placenta from its abdominal implantation sites 
in second and third trimester cases.11 MTX 
treatment causes severe abdominal pain and 
side effects; therefore, patient should be 
monitored closely. In addition, the serum  
β-hCG concentration should be assayed every 
week. In 15–20% of patients the serum β-hCG 
concentration has not declined by at least 25% 
in first week after drug use, and the next dose 
should be administered.12 Regarding MTX 
treatment, there are two regimens: multi-dose 
(MTX 1.0 mg/kg intramuscularly (IM) daily; 
days 0, 2, 4, and 6 alternated with folinic acid 
0.1 mg/kg orally on days 1, 3, 5, 7) and single 
dose (MTX 0.4 to 1.0 mg/kg or 50 mg/m2 IM 
without folinic acid).11 Researchers compared 
both regimens and concluded that the multi-
dose regimen was more effective than the 
single-dose regimen.13 According to the above 
information, this study was aimed to verify the 
possible association between response to the 
medical treatment and predicting factors in 
ectopic pregnancy among pregnant women 
referred to the Besat hospital, Sanandaj, Iran, 
during 2008–2013. 
Materials and Methods 
In a cross-sectional study, all women admitted 
to the obstetrics and gynecology ward of Besat 
hospital, Sanandaj City, during 2008 to 2013, 
who were diagnosed with EP, were included. 
Patients who received any medication before 
study or those who could not use MTX were 
excluded from study. The data were collected 
from patients’ dossiers. 
A logistic regression model was used to 
associate the contribution of underlying factors 
in predicting the serum level of -hCG after 
the medical intervention. The outcome was 
defined on the basis of -hCG levels. The 
absolute value of the -hCG was not of great 
importance; rather, -hCG level less than  
2000 mIU/ml indicated a high chance for 
ectopic pregnancy. Thus, the nature of the 
medical outcome is dichotomous: either -hCG 
falls below 2000 mIU/ml threshold or it is 
above this cut-off point. If the probability of 
changing the serum level of -hCG follows a 
logistic function, then its probability can be 
estimated by: 
 
 (   | )  
 
      
   
 
Where   is the list of predictors and   is their 
corresponding coefficients to be estimated. 
Results 
In this retrospective study, 277 patients with 
ectopic pregnancy were evaluated. 197 (71.1%) 
patients were younger than 35 years, and 205 
(74.1%) patients were successfully treated with 
medical treatment with MTX, while 72 (25.9%) 
patients required surgery. For each participant, 
several variables which were believed to 
influence the outcome of MTX treatment were 
recorded. The complete list of predictors is 
shown in table 1. 
The question of interest was whether there is 
any association between the probability of  
-hCG serum level less than 2000 mIU/ml with 
absence or presence of predictors. If there is not 
any association, then the determination of -hCG 
would not be useful for prediction. To account 
for this, the significance of the fitted logistic 
regression with full list of predictors (full model) 
was tested against a model without predictors 
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Response   
-hCG 1 - -hCG over 2000 mIU/ml; 0 – less than 2000 mIU/ml Dichotomous 
Predictor   
EP 1 - History of EP present; 0- no history of EP  Design 
PLSUR 1 - History of pelvic surgery; 0 – no history of pelvic surgery Design 
PID 1 - History of pelvic inflammatory disease; 0 – no History of pelvic inflammatory disease Design 
INFER 1 – Infertility problem present; 0 – no infertility problem Design 
IVF 1 - In vitro fertilization; 0 - no in vitro fertilization Design 
INTCRS 1 - First intercourse before 18; 0 – no intercourse before 18 Design 
ABORTION 1 - History of abortion; 0 – no history of abortion Design 
CS 1 – Birth by caesarean surgery; 0 – normal delivery Design 
Age Age of subject Continuous 
Sac4 1 - Pregnancy sac over 4cm; 0 – pregnancy less than 4cm Design 
FHR 1 - Fetal heart rate present; 0 – no fetal heart rate Design 
-hCG 5000 1 - -hCG level over 5000 mIU/ml; 0 – -hCG under 5000 mIU/ml Design 
EP: Ectopic pregnancy; PLSUR: Pelvic surgery; PID: Pelvic inflammatory disease; INFER: Infertility; IVF: In vitro fertilization; 
INTCRS: Intercourse; CS: Caesarean surgery; FHR: Fetal heart rate; -hCG: Beta human chorionic gonadotropin 
 
The result was highly significant, showing 
that there was a significant difference  
between the full model and the null model  
(           degree of freedom (df) = 2,  
P < 0.00001), which indicates the good prediction 
power of predictors. 
The results of fitting multiple logistic 
regression model showed that at        level, 
the pregnancy sac larger than 4 cm (Sac 4), fetal 
heart rate (FHR), and -hCG level over  
5000 mIU/ml are statistically significant, 
infertility problem and individual’s age are 
marginally significant, and other variables do 
not influence the level of -hCG. To evaluate the 
goodness-of-fit of the logistic model, 
McFadden’s pseudo R-square was used.14 For a 
good fit, this index should be between 0.2 and 
0.4.15 For multiple logistic regression model, 
McFadden’s pseudo R-square was obtained 0.46 
which indicates a good fit. Table 2 represents the 
coefficients and odds ratios of the logistic 
regression model containing all predictors. 
 
Table 2. Estimated coefficients and odds ratios for the logistic regression model containing all predictors 
Predictor Coefficient Standard Error Odds ratio Wald Statistics P 
EP 0.062 0.061 1.064 0.993 0.321 
PLSUR -0.102 0.062 0.903 -1.624 0.105 
PID 0.052 0.054 1.054 0.970 0.332 
INFER 0.032 0.061 1.032 0.522 0.602 
IVF -0.206 0.113 0.813 -1.823 0.067
*
 
INTCRS -0.039 0.049 0.962 -0.791 0.429 
ABORTION 0.082 0.051 1.085 1.614 0.108 
CS 0.058 0.053 1.060 1.115 0.266 
Age35 -0.090 0.047 0.913 -1.905 0.058
*
 
Sac4 -0.211 0.051 0.809 -4.119 < 0.001 
FHR  -0.316 0.085 0.728 -3.719 < 0.001 
-hCG 5000 -0.423 0.053 0.655 -7.950 < 0.001 
EP: Ectopic pregnancy; PLSUR: Pelvic surgery; PID: Pelvic inflammatory disease; INFER: Infertility; IVF: In vitro fertilization;  
INTCRS: Intercourse; CS: Caesarean surgery; FHR: Fetal heart rate; -hCG: Beta human chorionic gonadotropin 
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Table 3. Estimated coefficients and odds ratios for the logistic regression model containing three predictors 
Predictor Coefficient Standard Error Odds ratio Wald Statistics P 
Sac 4 -0.208 0.051 0.812 -4.037 < 0.001 
FHR -0.306 0.085 0.736 -3.606 < 0.001 
-hCG 5000 -0.441 0.053 0.643 -7.374 < 0.001 
FHR: Fetal heart rate; -hCG: Beta human chorionic gonadotropin 
 
For ease of interpretation and practical use, it 
is recommended to construct a reduced model 
with fewer predictors as possible. Thus, to 
eliminate the less significant variables form the 
full model (Table 2), the top-down strategy of 
Diggle was followed.16 Starting with the full 
model, the least significant covariate was 
determined based on Wald statistics and was 
dropped from the model. Likelihood ratio test 
(LRT) was applied to compare the initial and 
reduced model. The procedure proceeded until 
the LRT showed significant p-value, indicating 
no need for further reduction. The procedures 
led to excluding all marginal and non-significant 
design variables and ended up with a model 
including only the pregnancy sac larger than  
4 cm (SAC 4), FHR, and -hCG level over  
5000 mIU/ml. For this model, McFadden’s 
pseudo R-square reduced to 0.42 but still 
indicated a good fit. Table 3 represents the 
coefficients and odds ratios of the reduced 
logistic regression model. 
Interaction and confounding effects: The 
interaction effects of three variables (i.e. Sac  
4, FHR, and β-hCG 5000) were added to the final 
model to investigate whether there was any 
improvement in predicting the probability of 
increasing β-hCG level after medical 
intervention or not. In the same manner as 
discussed above, the LRT was used to 
discriminate between succeeding models. The 
process began with three significant predictors 
and their interactions. Top-down strategy found 
no significant interactions; as well as no 
confounding effects. 
Model interpretation: Increasing the -hCG 
level due to medical intervention tends to be 
linked with pregnancy sac larger than 4 cm  
(Sac 4). The estimated odds ratio is 0.812 or 
1/1.231 (95% CI: 0.05-0.78) which is less than 1.0, 
indicating that the probability of increasing the 
level of -hCG for a women with pregnancy sac 
larger than 4 cm is less than the probability of 
increasing the level of -hCG for a women with 
pregnancy sac less than 4 cm. Specifically, the 
odds ratio of -hCG growth would decrease by 
0.231 for a woman with a sac less than 4 cm. The 
logistic regression model also suggests that the 
absence of FHR increases the level of -hCG. The 
odds ratio of 0.736 (or 1/1.358) indicates that the 
probability of increase in the -hCG is  
1.358 times more than the probability of 
increasing the -hCG if FHR is detected. 
Furthermore, the baseline -hCG also affects the 
-hCG level after medical treatment in similar 
manner. The odds ratio of 0.643 (or 1/1.555) 
indicates that the probability of increasing the 
level of -hCG for a treated women with baseline 
-hCG over 5000 mIU/ml is 1.555 times more 
than that of for a treated women with baseline  
-hCG less than 5000 mIU/ml. 
Discussion 
The findings of this study showed that there 
was an association between the pregnancy sac 
≥ 4 cm and failure to the treatment. In this 
regard, Kimiaei et al. reported that pregnancy 
sac ≥ 3.5 cm is the most important predicting 
factor in response to the treatment.17 
In addition, according to the results it was 
found that the primary β-hCG serum  
level ≥ 5000 mIU/ml may be a predicting 
factor for treatment failure. This finding was in 
agreement with Saadati et al., who reported 
that in patients with higher serum level of  
β-HCG, the successful treatment increased by 
using double dose of MTX method. They 
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decrease the necessity of operation, re-
administration of MTX, and duration of 
hospitalization.18 In another study, serum level 
of β-hCG ≥ 6000 mIU/ml was the only 
predicting factor of treatment failure.19 
In agreement with the findings of the 
present study, Potter et al. reported that the 
median primary β-hCG serum level was lower 
in women with successful treatment compared 
to those women with treatment failure.20 
Another finding was the rate of successful 
treatment with MTX. In this study, 72 (25.9%) 
patients required surgery. In accordance with 
these results, Mirbolouk et al. reported that 
among 370 patients, 285 (77.1%) patients were 
successfully treated with MTX and 85 (22.9%) 
patients required surgery.21 
Furthermore, comparing to the present 
findings, compelling evidence suggests that 
there was no significant difference between 
groups regarding the age of patients, history of 
EP, infertility, abortion and location of ectopic 
mass; therefore, none of these factors could 
predict the success of drug treatment in this 
population.13,21,22 
In addition, in the present study, it was 
revealed that presence of FHR in patients was 
associated with reduced rate of successful 
medical treatment, which was in line with the 
findings of Lipscomb et al., who indicated that 
FHR in sonography is a predictor of treatment 
failure.22 
Conclusion 
Taking together, the results of this study 
suggest that there is a significant association 
between successful response to the treatment 
and β-hCG serum level, pregnancy sac size or 
presence of FHR; while age, history of 
infertility, number of abortion, history of EP, 
history of pelvic infection or surgery, 
nulliparity, history of smoking, and caesarean 
were not predictors of treatment failure. 
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